MedTrace Logo

Tableted COVID-19 Therapeutic Vaccine

NCT04380532 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-05-27

No results posted yet for this study

Summary

Safety and immunogenicity one-month study in healthy individuals administered once-daily pill of therapeutic vaccine made from heat-inactivated plasma from donors with COVID-19. Healthy, at least 20, volunteers will be monitored for signs of adverse events. Their PBMC will be collected at baseline and one month later to analyze which type of immune response vaccine has induced.

Conditions

  • Covid19

Interventions

BIOLOGICAL

V-SARS

Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month

Sponsors & Collaborators

  • Immunitor Inc.

    collaborator INDUSTRY

  • Immunitor LLC

    lead INDUSTRY

Principal Investigators

  • Aldar Bourinbayar, MD/PhD · Immunitor LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-15
Primary Completion
2021-05-15
Completion
2021-06-15

Countries

  • Canada
  • Mongolia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04380532 on ClinicalTrials.gov